Condition
Vein Occlusion
Total Trials
4
Recruiting
1
Active
2
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
50%
1 of 2 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (2)
P 4 (2)
Trial Status
Completed2
Active Not Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05409976Not ApplicableActive Not Recruiting
The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study
NCT05489588Not ApplicableRecruiting
The GORE® VIABAHN® FORTEGRA Venous Stent Iliofemoral Study
NCT03900026Phase 4Completed
Effect of Evolocumab on Saphenous Vein Graft Patency Following Coronary Artery Bypass Surgery
NCT07090044Phase 4CompletedPrimary
Comparing Post-intravitreal Injection Pain Scores Using Loteprednol, Bromfenac Sodium, and Artificial Tears Over a 24-hour Period
Showing all 4 trials